KARDIA-3

Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk

PURPOSE: To assess the impact of zilebesiran as an adjunct treatment in patients with elevated cardiovascular risk and uncontrolled hypertension in addition to multiple antihypertensive therapies.

STUDY DESIGN: Phase 2, randomized, double-blind, placebo-controlled trial, N=270

KEY TAKEAWAYS: A single zilebesrian injection reduced mean office systolic blood pressure (SBP) at 3 months compared to placebo, but the difference was not statistically significant after multiplicity adjustment.

	Zilebesiran 300 mg	P value (95% CI)	Zilebesiran 600 mg	P value (95% CI)	Hochberg Multiplicity adjustment
Primary outcome					
Placebo-adjusted change from baseline in office SBP (mmHg) at 3 month	-5.0	0.04 (-9.9 to -0.2)	-3.3	0.18 (-8.2 to 1.6)	Not significant
RESULTS: A single-dose injection of zilebesiran reduced mean office SBP at 3 months compared to placebo; however, this difference did not reach statistical significance after adjusting for multiplicity.					